Disease progression modeling with temporal realignment: An emerging approach to deepen knowledge on chronic diseases

IF 12 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pharmacology & Therapeutics Pub Date : 2024-05-04 DOI:10.1016/j.pharmthera.2024.108655
Hideki Yoshioka , Ryota Jin , Akihiro Hisaka , Hiroshi Suzuki
{"title":"Disease progression modeling with temporal realignment: An emerging approach to deepen knowledge on chronic diseases","authors":"Hideki Yoshioka ,&nbsp;Ryota Jin ,&nbsp;Akihiro Hisaka ,&nbsp;Hiroshi Suzuki","doi":"10.1016/j.pharmthera.2024.108655","DOIUrl":null,"url":null,"abstract":"<div><p>The recent development of the first disease-modifying drug for Alzheimer's disease represents a major advancement in dementia treatment. Behind this breakthrough is a quarter century of research efforts to understand the disease not by a particular symptom at a given moment, but by long-term sequential changes in multiple biomarkers. Disease progression modeling with temporal realignment (DPM-TR) is an emerging computational approach proposed with this biomarker-based disease concept. By integrating short-term clinical observations of multiple disease biomarkers in a data-driven manner, DPM-TR provides a way to understand the progression of chronic diseases over decades and predict individual disease stages more accurately. DPM-TR has been developed primarily in the area of neurodegenerative diseases but has recently been extended to non-neurodegenerative diseases, including chronic obstructive pulmonary, autoimmune, and ophthalmologic diseases. This review focuses on opportunities for DPM-TR in clinical practice and drug development and discusses its current status and challenges.</p></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"259 ","pages":"Article 108655"},"PeriodicalIF":12.0000,"publicationDate":"2024-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0163725824000755","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The recent development of the first disease-modifying drug for Alzheimer's disease represents a major advancement in dementia treatment. Behind this breakthrough is a quarter century of research efforts to understand the disease not by a particular symptom at a given moment, but by long-term sequential changes in multiple biomarkers. Disease progression modeling with temporal realignment (DPM-TR) is an emerging computational approach proposed with this biomarker-based disease concept. By integrating short-term clinical observations of multiple disease biomarkers in a data-driven manner, DPM-TR provides a way to understand the progression of chronic diseases over decades and predict individual disease stages more accurately. DPM-TR has been developed primarily in the area of neurodegenerative diseases but has recently been extended to non-neurodegenerative diseases, including chronic obstructive pulmonary, autoimmune, and ophthalmologic diseases. This review focuses on opportunities for DPM-TR in clinical practice and drug development and discusses its current status and challenges.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
通过时间调整建立疾病进展模型:深化慢性疾病知识的新兴方法。
最近开发出的第一种治疗阿尔茨海默病的改变病情药物代表了痴呆症治疗领域的一大进步。在这一突破的背后,是四分之一世纪以来的研究努力,即不是通过特定时刻的特定症状,而是通过多种生物标志物的长期连续变化来了解疾病。基于时间调整的疾病进展建模(DPM-TR)是根据这种基于生物标志物的疾病概念提出的一种新兴计算方法。通过以数据驱动的方式整合多种疾病生物标志物的短期临床观察结果,DPM-TR 提供了一种了解慢性疾病数十年进展的方法,并能更准确地预测疾病的各个阶段。DPM-TR 主要是在神经退行性疾病领域开发的,但最近已扩展到非神经退行性疾病,包括慢性阻塞性肺病、自身免疫性疾病和眼科疾病。本综述将重点介绍 DPM-TR 在临床实践和药物开发中的机遇,并讨论其现状和挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
23.00
自引率
0.70%
发文量
222
审稿时长
90 days
期刊介绍: Pharmacology & Therapeutics, in its 20th year, delivers lucid, critical, and authoritative reviews on current pharmacological topics.Articles, commissioned by the editor, follow specific author instructions.This journal maintains its scientific excellence and ranks among the top 10 most cited journals in pharmacology.
期刊最新文献
Pro-resolving lipid mediators and therapeutic innovations in resolution of inflammation. The pharmacodynamic and pharmacological mechanisms underlying nanovesicles of natural products: Developments and challenges. Exploring the landscape of post-translational modification in drug discovery. New drug discovery and development from natural products: Advances and strategies. Neurobiology of cancer: Adrenergic signaling and drug repurposing
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1